Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of Lilly’s tirzepatide, the active ingredient in Zepbound, and generics of ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Looking from left to right truly shows how GLP-1 influenced growth and commercial viability. That spotlights the importance of HIMS really getting control over what treatments it can and can’t ...

The PSM claims in its letter to the FDA that the commercial is "dangerous ... particularly with complex injectable products like Hims & Hers is advertising," he added. "The FDA says compounded ...

Hims & Hers stock price has imploded this year ... having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the ...

Trident Digital Tech Holdings, Tesla, Hims & Hers Health, and SoFi Technologies experience notable market activity ...

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine ... including BeiGene, Hims & Hers Health and Progyny. “electroCore ...